bluuebunny/crossref_metadata_2025 huggingface dataset:
Abstract 671: Exploiting macrophage differentiation and plasticity as an immunomodulating strategy
Authors: Castro Carla , Metzger Philipp , Obodozie Cynthia , Weber Holger
Published: April 2023

The infiltration of macrophages into the tumor microenvironment (TME) is a well-known characteristic of tumor progression and therapy resistance. Depending on the signals derived from TME, macrophage plasticity allows them to undergo a variety of polarization states. Two extremes of macrophage polarization are M1 and M2 phenotypes. M1 macrophages provide enhanced anti-tumor inflammatory reaction while M2 macrophages are usually associated with tumor progression due to their immune suppression, angiogenesis and neovascularization promoting capabilities. Modulating the macrophage differentiation or polarization has emerged as a therapeutic strategy to synergize or complement current treatments.

At Reaction Biology we have established human macrophage assay pipelines to evaluate the novel macrophage polarization compounds in vitro. Both, monocyte cell lines like THP-1, and and freshly isolated monocytes from donor derived PBMCs, are of great value. Donor derived differences could become an issue during the screening phase compared to the use of cell lines. Yet, after the screening phase, the evaluation across several healthy donors is crucial to assess the impact of a compound on the general population. Monocytes from primary human peripheral blood mononuclear cell (PBMC) are isolated, differentiated into naïve macrophages, and polarized. Effects of compounds modulating the differentiation and polarization of macrophages are analyzed by flow cytometry. Moreover, the functional reprogramming of monocytes and macrophages can be analyzed by measuring the phagocytic or tumor cell killing capacity via flow cytometry or using high content screening equipment. In the addition, a wide range of secreted cytokine can be quantified by MSD ELISA.

Our data shows that human primary monocytes grown under M1 polarizing conditions express high levels of CD86 and HLA-DR in contrast to those cultivated under M2 polarizing conditions, with high expression of CD163 and CD206. A pH-sensitive phagocytosis could be shown for M2 macrophages. Modulation of surface markers from polarized macrophages under different treatment conditions could be observed, as well as changes in their functionality, supporting the translational value to evaluate the efficacy of immunomodulating compounds in vitro.

Citation Format: Carla Castro, Philipp Metzger, Cynthia Obodozie, Holger Weber. Exploiting macrophage differentiation and plasticity as an immunomodulating strategy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 671.
Abstract 6768: The potential predictive role of spatial phenotyping in non-small cell lung cancer
Authors: Ma Ning , Pratapa Aditya , Monkman James , O’Byrne Ken , Braubach Oliver , Kulasinghe Arutha
Published: April 2023

Background Lung cancers are the leading cause of cancer-related deaths with a 5-year-survival of only ~20%. Whilst immunotherapies have led to durable and prolonged survival, only a subset of patients remain responsive. Additional biomarkers are thus needed to better predict if patients will respond or develop resistance against immune checkpoint inhibitor (ICI) therapies. Spatial phenotyping of the tumor microenvironment (TME) is now recognized as a proxy for ICI therapy outcomes. Our study employs an end-to-end spatial biology strategy to survey non-small-cell lung cancer (NSCLC) tissues for new biomarkers that could guide immunotherapy treatments.

Methods We phenotyped pre-treatment biopsies from non-small-cell lung cancer (NSCLC) patients treated with single-agent Nivolumab. We first performed 57-plex whole-slide Single Cell Spatial Phenotyping on the PhenoCycler®-Fusion platform. Next, we developed the spatial analysis of a larger NSCLC cohort using customizable PhenoCode Signature Panels (PSP) for high-throughput immune profile (CD3/CD8/CD20/CD68/PanCK + CD4 add-in) and immuno-contexture (CD8/CD68/PD-L1/FoxP3/PanCK + PD-1 add-in) imaging. The PSP panel content combines the barcode-based antibody chemistry from the PhenoCycler platform with the signal amplification of Opal chemistry from the PhenoImager platform. PSP panels were profiled across n=27 NSCLC biopsies and provided a wider breadth of tissue profiling.

Results Our whole-slide single-cell spatial phenotyping analyses revealed high phenotypic diversity in the TME of patients responsive and resistant to ICI therapy. However, higher-throughput analyses of the same tissues using targeted PSP panels revealed no significant differences in quantities of immune cell lineages, including T-cells and macrophages. On the contrary, we discovered multiple quantifiable and statistically significant spatial signatures that appear to be predictive of treatment benefit, which confirms the potential biomarker value of spatial associations in patient tissues.

Conclusions This study amounts to a uniquely comprehensive Single Cell Spatial Phenotyping analysis of pre-treatment NSCLC biopsies from a single-agent Nivolumab study. Our data catalogue the diversity in the immune microenvironment of NSCLC but highlighted that immune cell quantification is insufficient to stratify patient cohorts. Single-cell spatial phenotyping, on the other hand, promises to reveal new biomarkers that may aid in better stratification of patients in pre-treatment evaluations.

Citation Format: Ning Ma, Aditya Pratapa, James Monkman, Ken O’Byrne, Oliver Braubach, Arutha Kulasinghe. The potential predictive role of spatial phenotyping in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6768.
Abstract 677: Increasing plexity of imaging mass cytometry for tumor tissue analysis
Authors: Pfister Thomas D. , Ouladan Shaida , Yao Huihui , Majonis Daniel , Loh Christina , Zabinyakov Nick
Published: April 2023

Imaging Mass Cytometry™ (IMC™) is the leading platform for high-plex tissue imaging. IMC allows for detailed assessment of cell phenotype and function using 40-plus markers simultaneously at subcellular resolution on a single slide. A comprehensive IMC panel containing structural, functional, and immune markers enables us to reveal the complex heterogeneity of tumor tissues as well as the tumor microenvironment (TME). Driven by an increase in the number of antibody markers and the addition of mRNA markers, there is an increasing demand for larger panels. In addition, increasing the number of investigated target markers on a single tissue enriches spatial characterization that may facilitate a more accurate prediction of disease progression and preclinical outcome measures in clinical research projects using tumor biopsies or tissue microarrays (TMAs). Therefore, to increase the plexity of IMC panels, it is essential to expand the number of available metal channels. Here, we demonstrate the incorporation of conjugated antibodies with yttrium (89Y) and indium (115In), two low-mass metals, for IMC application. These metal tags have been previously tested as putative channels for IMC application.

We performed IMC analysis of various tissue types stained with panels of conjugated antibodies including the novel 89Y- and 115In-conjugated antibodies. At least 3 different regions of interest (ROIs) were assessed for each of the investigated tissue types. We compared images for the 89Y- and 115In-conjugated antibodies with the images generated using Maxpar® catalog antibodies of the same clones, with a focus on marker specificity and background signal. Compared with the lanthanide-conjugated catalog antibodies, the 89Y- and 115In-conjugated antibodies showed equivalent specificity and staining quality.

Our results open a new avenue to assign markers to 89Y and 115In, which enables a larger list of potential targets to be investigated in any IMC study. Expanding the number of markers to 40-plus in Imaging Mass Cytometry will improve the imaging results necessary to identify novel cell signatures (phenotype and interactions) in the TME.

Citation Format: Thomas D. Pfister, Shaida Ouladan, Huihui Yao, Daniel Majonis, Christina Loh, Nick Zabinyakov. Increasing plexity of imaging mass cytometry for tumor tissue analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 677.
Abstract 682: Heterologous prime-boost viral vector vaccines for the treatment of a P1A-expressing BGL-1 glioblastoma model
Authors: Steffke Emily E. , McAuliffe James , Almeida Vinnycius Pereira , Wicki Amanda , Noblecourt Laurine , Kohanbash Gary , Okada Hideho , Leung Carol Sze Ki , Terabe Masaki , Eynde Benoit J. Van Den
Published: April 2023

Glioblastoma is an extremely aggressive and difficult cancer to treat, which may partly be due to its limited ability to induce T-cell responses. However, combining viral vector vaccines with other therapies to generate tumor-specific T cells may provide a meaningful benefit to patients. Here, we investigated whether heterologous prime-boost vaccination with chimpanzee-derived adenoviral vector ChAdOx1 and modified vaccinia Ankara (MVA) vaccines could generate therapeutically effective CD8+ T-cell responses against a model antigen P1A, a mouse homolog of human tumor-associated Melanoma Antigen GenE (MAGE)-type antigens, expressed by a BGL-1 mouse glioblastoma cell line. We demonstrated that heterologous prime-boost vaccination with ChAdOx1/MVA vaccines targeting P1A generated a high magnitude of CD8+ T cells specific for the P1A35-43 epitope presented by the MHC class I molecule H-2Ld. Prophylactic vaccination with ChAdOx1/MVA-P1A significantly prolonged the survival of syngeneic mice subcutaneously challenged with P1A-expressing BGL-1 tumors. Furthermore, different vaccination schedules significantly impact the magnitude of antigen-specific CD8+ T-cell responses and may impact protective efficacy. However, the substantial induction of myeloid-derived suppressor cells (MDSCs) by this tumor model presents a significant challenge in the therapeutic setting. Future work will investigate the efficacy of this vaccination strategy on intracranial P1A-expressing BGL-1 models.

Citation Format: Emily E. Steffke, James McAuliffe, Vinnycius Pereira Almeida, Amanda Wicki, Laurine Noblecourt, Gary Kohanbash, Hideho Okada, Carol Sze Ki Leung, Masaki Terabe, Benoit J. Van Den Eynde. Heterologous prime-boost viral vector vaccines for the treatment of a P1A-expressing BGL-1 glioblastoma model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 682.
Abstract 692: OAd-mediated SA-4-1BBL fused to HPV-16 E7 elicits specific antitumor efficacy in syngeneic mouse lung cancer model
Authors: Gomez-Gutierrez Jorge G. , Garza-Morales Rodolfo , Martinez-Perez Alejandra G. , Perez-Trujillo Jose J. , Saucedo-Cardenas Odila , Loera-Arias Maria J. , Montes-de-Oca-Luna Roberto
Published: April 2023

Introduction: Human papillomaviruses (HPVs) are responsible for about 25% of cancer cases worldwide. HPV-16 E7 antigen is a tumor-associated antigen (TAA) commonly expressed in HPV-induced tumors; however, it has low immunogenicity. The interaction of 4-1BBL with its receptor induces pleiotropic effects on innate, adaptive, and regulatory immunity and, if fused to TAAs in DNA vaccines, can improve the antitumor response; however, there is low transfection and antitumor efficiency. Oncolytic virotherapy is promising for antitumor gene therapy as it can be selectively replicated in tumor cells, inducing cell lysis, and furthermore, tumor cell debris can be taken in by immune cells to potentiate antitumor responses.

Methods: The AdenoQuick 2.0 system was used to construct three OAds, expressing 1) SP-SA-E7-4-1BBL, 2) SA-E7-4-1BBL or 3) SP-SA-41BBL. The expression of transgenes was confirmed by western blot and subcellular localization of SP-SA-E7-4-1BBL was evaluated by immunofluorescence. The recombinant OAds-mediated cancer killing effect was evaluated by MTT assay and crystal violet staining, The recombinant OAds therapeutic efficacy was evaluated in a C57BL/6 mice bearing subcutaneous TC-1 lung tumor. Tumor growth and survival were monitored for a period of twenty-eight days.

Results: In this study, we expressed the immunomodulatory molecule SA-4-1BBL fused to E7 on an oncolytic adenovirus (OAd) system. In vitro infection of TC-1 tumor cells and NIH-3T3 non-tumor cells with SA/E7/4-1BBL OAd demonstrated that only tumor cells are selectively destroyed. Moreover, protein expression is targeted to the endoplasmic reticulum in both cell lines when a signal peptide (SP) is added. Finally, in an HPV-induced cancer murine model, the therapeutic oncolytic activity of OAd can be detected, and this can be improved when fused to E7 and SP.

Conclusions: In this study, we report the design of an oncolytic adenovirus expressing the SP/SA/E7/4-1BBL fusion gene, which is capable of infecting murine cancer and normal cells, and the expressed protein was able to be targeted to the endoplasmic reticulum. Most importantly, OAd induced a cell killing effect that is specific to cancer cells. Moreover, OAd treatment induced a potent antitumor effect in a mouse TC-1 cancer model.

Citation Format: Jorge G. Gomez-Gutierrez, Rodolfo Garza-Morales, Alejandra G. Martinez-Perez, Jose J. Perez-Trujillo, Odila Saucedo-Cardenas, Maria J. Loera-Arias, Roberto Montes-de-Oca-Luna. OAd-mediated SA-4-1BBL fused to HPV-16 E7 elicits specific antitumor efficacy in syngeneic mouse lung cancer model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 692.
Abstract 70: Mechanisms of tumor dormancy induction mediated by abrogation of myeloid tgfβ signaling
Authors: Ahad Abdul , Leng Feng , Ichise Hiroshi , Gray Justin , Aprelikova Olga , O’Neill Maura , Holewinski Ronald , Kopardé4 Vishal N. , Moriwaki Yasuhiro , Hollander Christine , Germain Ronald , Andresson Thorkell , Li Yang
Published: April 2023

Persistence in a dormant state of residual tumor cells can occur following extended periods of clinical remission which may last decades. The disseminated tumor cells in distant organ sites eventually gain context dependent metastasis advantage during tumor progression. The mechanisms for dormancy induction or reactivation remain unclear. We found that the abrogation of myeloid TGF-β signaling induced tumor dormancy in breast cancer metastasis models. When given extended time, the TGFβRIImyeKO mice eventually developed similar number of metastatic nodules to that of control mice. We further validated our finding using an inducible system where reintroduction of TβRII diminished the tumor dormancy induction. RNAseq of dormant vs proliferative tumor cells identify 504 differential expressed genes, including those involving cell cycle arrest, IFNg response, MTOR signaling as well as MYC targeted genes. Immune cell profiling showed differential immune composition in micro and macro-tumor microenvironment between WT and TβRIImyeKO lung tissues. Of great interest, abrogation of myeloid specific TGF-β signaling increased the number of CD103+DCs that displayed elevated TNFa production, which in turn increased IFNg+ production in T cells leading to improved innate

and adaptive immunity. Importantly, depletion of CD103 DCs in tumor-bearing TβRIImyeKO mice diminished the dormancy phenotype, which was not observed for the pDC depletion in the WT control mice. These data demonstrate that abrogation of myeloid specific TGF-β signaling improved the immune microenvironment, which induced tumor dormancy. Our data provide mechanistic insight and resources to understand the tumor dormancy.

Citation Format: Abdul Ahad, Feng Leng, Hiroshi Ichise, Justin Gray, Olga Aprelikova, Maura O’Neill, Ronald Holewinski, Vishal N. Kopardé4, Yasuhiro Moriwaki, Christine Hollander, Ronald Germain, Thorkell Andresson, Yang Li. Mechanisms of tumor dormancy induction mediated by abrogation of myeloid tgfβ signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 70.
Abstract 728: Socio-economic and health disparity determinants of breast cancer prevalence in low-income counties in Alabama and Mississippi: An analysis of Deep South cancer epidemic
Authors: Alagan Ram
Published: April 2023

Background: Studies underscore evidence that socioeconomic status (SES) is associated with breast cancer (BC)prevalence and especially poor SES is closely related to the cancer epidemic. Exploring the high and low SES status concerning BC prevalence is timely and noteworthy. Two impoverished Deep South states Alabama and Mississippi are the focus of this research. Alabama and Mississippi are well known for the historical and cultural landscape of Black Belt Counties (BBC), predominantly occupied by African American populations who were systematically undermined in many socioeconomic, healthcare, educational, and political aspects. Our investigation explores BC prevalence in the major ethnic groups (African American and White) in both southern states, mainly in the BBC.

Hypothesis/Objectives: We hypothesized that SES is closely associated with BC prevalence. In particular, the poor status of SES severely influences BC patients' access to healthcare, healthy food, obesity, education, employment, transportation, prevention, and screening. Our study explores the impact of selected SES factors to understand BC prevalence in both states, particularly in impoverished BBC.

Methods: We utilized Geospatial Technology (GT) to analyze the connection between BC prevalence and SES. This study incorporates county-level BC prevalence and association with SES, education, healthy food access, and health disparities. A robust data mining (U.S. Census, State Cancer Profile, Department of Health, American cancer society, National Cancer Institute, and published peer-reviewed journals) enabled us to explore the association between BC in the geospatial context. Integrating geospatial and non-spatial data on BC prevalence with SES will help predict and formulate BC prevention methods and promote health policy formulation and intervention in deep southern states.

Conclusions: Alabama and Mississippi are the top states concerning the BC epidemic. The research employed SESand cancer prevalence using GT. Data shows a close relation between SES and cancer prevalence. The research strongly recommends the states adopt cancer awareness programs, and social and health equity policy planning.

Citation Format: Ram Alagan. Socio-economic and health disparity determinants of breast cancer prevalence in low-income counties in Alabama and Mississippi: An analysis of Deep South cancer epidemic [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 728.
Abstract 932: Snapshot! Exploring sample diversity of sarcoma cancers across common data repositories
Authors: Gonzalez Alfredo Enrique , Patel Yash , Zhu Chenghao , Yamaguchi Takafumi N. , Tian Mao , Hiyari Sarah , Shihabi Ahmad A. , Eng Stefan , Winata Helena , Arbert Jaron , Beshlikyan Arpi , Davarifar Ardalan , Soragni Alice , Boutros Paul C.
Published: April 2023

Sarcoma is a cancer which originates in the body's connective tissues of mesenchymal origin. These are tissues like bones and muscles that support or protect other parts of the body. About ~16,000 sarcomas are diagnosed annually in the US, with ~6,700 deaths attributed to the disease. Sarcomas are typically divided into two major groups: bone sarcomas and soft-tissue sarcomas, each of which has multiple subtypes. However, because of their diversity in site-of-origin, sarcomas vary greatly in their presentation and histological features. Based on The World Health Organization’s (WHO) current classification system that categorizes musculoskeletal soft tissue tumours (STT) and bone tissue tumours, there are 50+ subtypes of sarcoma recognized today. Unsurprisingly, given the relative rarity of sarcoma type tumors, sample procurement has proved a challenge for the field. Consequently, there currently exist major gaps in our understanding of the genetic and molecular hallmarks of various sarcoma subtypes. Here we examine the sample and subtype classifications of sarcoma across some of the major DNA sequencing studies and data repositories to provide an overview of the available sample space. We highlight areas where the sample procurement is lagging and discuss subtypes that are missing all-together. Inclusion of some of the major genomic correlates showcases some of the similarities shared by these sequencing efforts, while emphasizing key genetic differences between subtypes. This work provides a clear roadmap for clinicians on how to best prioritize future sarcoma sample procurement and sequencing.

Citation Format: Alfredo Enrique Gonzalez, Yash Patel, Chenghao Zhu, Takafumi N. Yamaguchi, Mao Tian, Sarah Hiyari, Ahmad A. Shihabi, Stefan Eng, Helena Winata, Jaron Arbert, Arpi Beshlikyan, Ardalan Davarifar, Alice Soragni, Paul C. Boutros. Snapshot! Exploring sample diversity of sarcoma cancers across common data repositories [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 932.
Abstract PL05-03: What if all your favorite proteins are druggable
Authors: Bowman Gregory R.
Published: April 2023

Many proteins that play key roles in cancer are considered difficult drug targets, if not entirely undruggable, due to an apparent lack of pockets where small molecules can bind with the affinity and specificity required for a drug. ‘Cryptic’ pockets that are absent in known structures of proteins but form due to protein dynamics could alleviate this problem. However, it has been hard to assess or exploit the opportunities that cryptic pockets present due to the inherent difficulty in identifying such pockets. Here, I will discuss progress from my lab on combining biophysical experiments, computer simulations, and machine learning to identify and target cryptic pockets. In one case study, we have used computer simulations deployed on the Folding@home distributed computing environment to predict a cryptic pocket that can allosterically control a protein-RNA interaction, and then experimentally confirmed our predictions. Based on data from this study and others in our lab, we have trained a machine learning algorithm to predict where cryptic pockets are likely to form from single protein structures, enabling us to assess how prevalent cryptic pockets are on a large scale.

Citation Format: Gregory R. Bowman. What if all your favorite proteins are druggable. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr PL05-03.
Abstract SY17-01: The complexities of tumor associated macrophages and the key to effective targeting for anti-cancer therapy
Authors: Guerriero Jennifer L.
Published: April 2023

Despite objective responses to poly(ADP-ribose) polymerase (PARP) inhibition and improvements in progression-free survival (PFS) compared to standard chemotherapy in patients with BRCA-associated triple-negative breast cancer (TNBC), benefits are transitory. Using high-dimensional single-cell profiling of human TNBC, here we demonstrate that macrophages are the predominant infiltrating immune cell type in breast cancer susceptibility (BRCA)-associated TNBC. Macrophages are an innate immune cell that play a critical role in host defense and maintaining tissue homeostasis, however their infiltration into tumors has been associated with disease progression and resistance to therapy. Tumor associated macrophages (TAMs) represent a significant proportion of solid tumors, including breast cancer. TAMs play a major role in tumorigenesis as they can enhance tumor cell growth, angiogenesis and metastasis. In addition, TAMs can inhibit anti-tumor responses of T cells. Our recent work has shown that removal or conversion of TAMs to an anti-tumor phenotype enhances chemo- and immuno-therapy establishing TAMs as targets for anti-cancer therapy. Through multi-omics profiling, we show that PARP inhibitors enhance both anti- and pro-tumor features of macrophages through glucose and lipid metabolic reprogramming, driven by the sterol regulatory element-binding protein 1 (SREBF1, SREBP1) pathway. Combining PARP inhibitor therapy with colony-stimulating factor 1 receptor (CSF1R)-blocking antibodies significantly enhanced innate and adaptive antitumor immunity and extended survival in mice with BRCA-deficient tumors in vivo, and this was mediated by CD8+ T cells. Collectively, our results uncover macrophage-mediated immune suppression as a liability of PARP inhibitor treatment and demonstrate that combined PARP inhibition and macrophage-targeting therapy induces a durable reprogramming of the tumor microenvironment (TME), thus constituting a promising therapeutic strategy for TNBC. Therefore, targeting TAMs offers great potential to enhance both chemo- and immuno-therapy. Deep analysis of TAMs in solid tumors has revealed the complexity of TAMs and revealed major gaps in our knowledge of the functional and phenotypic characterization of TAM subsets associated with cancer, before and after treatment. Here we will discuss the complexity of TAMs in solid tumors including characterizing TAM subsets, location, and crosstalk with neighboring cells, as well as novel TAM-modulating strategies and combinations that are likely to enhance current therapies and overcome chemo- and immuno-therapy resistance.

Citation Format: Jennifer L. Guerriero. The complexities of tumor associated macrophages and the key to effective targeting for anti-cancer therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr SY17-01.
Supplementary Data from CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric Tumorigenesis
Authors: Choi Sang Il , Yoon Changhwan , Park Mi Ree , Lee DaHyung , Kook Myeong-Cherl , Lin Jian-Xian , Kang Jun Hyuk , Ashktorab Hassan , Smoot Duane T. , Yoon Sam S. , Cho Soo-Jeong
Published: April 2023

Supplementary Figures
Supplementary Figure 2 from A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice
Authors: Pannellini Tania , Iezzi Manuela , Liberatore Marcella , Sabatini Federica , Iacobelli Stefano , Rossi Cosmo , Alberti Saverio , Di Ilio Carmine , Vitaglione Paola , Fogliano Vincenzo , Piantelli Mauro
Published: April 2023

Supplementary Figure 2 from A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice
Supplementary Figure 1 from Oncogenic Function and Early Detection Potential of miRNA-10b in Oral Cancer as Identified by microRNA Profiling
Authors: Lu Ya-Ching , Chen Yin-Ju , Wang Hung-Ming , Tsai Chi-Ying , Chen Wen-Ho , Huang Yu-Chen , Fan Kang-Hsing , Tsai Chi-Neu , Huang Shiang-Fu , Kang Chung-Jan , Chang Joseph Tung-Chieh , Cheng Ann-Joy
Published: April 2023

PDF file - 135K
Supplementary Figures and Tables from Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial
Authors: Safaeian Mahboobeh , Porras Carolina , Pan Yuanji , Kreimer Aimee , Schiller John T. , Gonzalez Paula , Lowy Douglas R. , Wacholder Sholom , Schiffman Mark , Rodriguez Ana C. , Herrero Rolando , Kemp Troy , Shelton Gloriana , Quint Wim , van Doorn Leen-Jan , Hildesheim Allan , Pinto Ligia A.
Published: April 2023

Fig. S1A: Individual HPV16 kinetics among the 1 dose group. Fig. S1B: Individual HPV18 kinetics among the 1 dose group. Fig. S1C: Individual HPV16 kinetics among the 2-dose(0/1) group. Fig. S1D: Individual HPV18 kinetics among the 2-dose(0/1) group. Fig. S1E: Individual HPV16 kinetics among the 2-dose(0/6) group. Fig. S1F: Individual HPV18 kinetics among the 2-dose(0/6) group. Fig. S1G: Individual kinetics HPV16 among the 3-dose group. Fig. S1H: Individual kinetics HPV18 among the 3-dose group. Fig. S2A: Relation of HPV16 antibody levels at 12 months and 48 months among women who received one vaccine dose. Fig. S2B: Relation of HPV18 antibody levels at 12 months and 48 months among women who received one vaccine dose. Table S1: Comparison of selected enrollment characteristics by vaccine dose group.
Supplementary Table 6 from Aberrant DNA Methylation at Genes Associated with a Stem Cell-like Phenotype in Cholangiocarcinoma Tumors
Authors: Sriraksa Ruethairat , Zeller Constanze , Dai Wei , Siddiq Afshan , Walley Andrew J. , Limpaiboon Temduang , Brown Robert
Published: April 2023

PDF file - 337K, List of genes associated with hypomethylated CpG sites in 6 CCA compared to 6 matched adjacent normal samples.
Supplementary Table 1 from No Decreased Risk of Gastrointestinal Cancers in Users of Metformin in The Netherlands; A Time-Varying Analysis of Metformin Exposure
Authors: de Jong Roy G. , Burden Andrea M. , de Kort Sander , van Herk-Sukel Myrthe P. , Vissers Pauline A. , Janssen Paddy K. , Haak Harm R. , Masclee Ad A. , de Vries Frank , Janssen-Heijnen Maryska L.
Published: April 2023

Supplementary Table 1. Hazard ratios of GI cancer overall by sex
Supplementary tables and figure from Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells
Authors: Zumwalt Timothy J. , Wodarz Dominik , Komarova Natalia L. , Toden Shusuke , Turner Jacob , Cardenas Jacob , Burn John , Chan Andrew T. , Boland C. Richard , Goel Ajay
Published: April 2023

SYBR green qRT-PCR Primers .
Table S1 from Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk
Authors: Barry Elizabeth L. , Fedirko Veronika , Uppal Karan , Ma Chunyu , Liu Ken , Mott Leila A. , Peacock Janet L. , Passarelli Michael N. , Baron John A. , Jones Dean P.
Published: April 2023

Table S1 shows metabolic features with confirmed or putative identities.
Figure S1 from Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk
Authors: Barry Elizabeth L. , Fedirko Veronika , Uppal Karan , Ma Chunyu , Liu Ken , Mott Leila A. , Peacock Janet L. , Passarelli Michael N. , Baron John A. , Jones Dean P.
Published: April 2023

Figure S1 shows changes in aspirin catabolite intensities between baseline and year 3 blood plasma samples.
Supplementary Figure from Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer
Authors: Mazumdar Abhijit , Tahaney William M. , Hill Jamal L. , Zhang Yun , Ramachandran Sumankalai , Kawedia Jitesh , Qian Jing , Contreras Alejandro , Savage Michelle I. , Vornik Lana A. , Sei Shizuko , Mohammed Altaf , Brown Powel H.
Published: April 2023

Supplementary Figure from Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer
Supplementary Tables and Figure from Colon Cancer Prevention with Walnuts: A Longitudinal Study in Mice from the Perspective of a Gut Enterotype–like Cluster
Authors: Chen Yanfei , Nakanishi Masako , Bautista Eddy J. , Qendro Veneta , Sodergren Erica , Rosenberg Daniel W. , Weinstock George M.
Published: April 2023

Supplementary Tables 1-4 and Supplementary Figure 1
Supplemental Figure 1 from Benefits of Multifaceted Chemopreventives in the Suppression of the Oral Squamous Cell Carcinoma (OSCC) Tumorigenic Phenotype
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Schwendeman Steven P. , Nieto Kari , Spinney Richard , Tong Meng , Koutras George , Han Brian , Holpuch Andrew , Lang James
Published: April 2023

Characterization of cell lines (cytokeratin and vimentin) and matched tumor tissues (IHC pSTAT3 and pEGFR).
Supplementary Data from Oral Microbiome Profiling in Smokers with and without Head and Neck Cancer Reveals Variations Between Health and Disease
Authors: Sharma Ashok Kumar , DeBusk William T. , Stepanov Irina , Gomez Andres , Khariwala Samir S.
Published: April 2023

Supplementary Data
Supplementary Figure from Combined Performance of Fecal Immunochemical Tests and a Genetic Risk Score for Advanced Neoplasia Detection
Authors: Niedermaier Tobias , Guo Feng , Weigl Korbinian , Hoffmeister Michael , Brenner Hermann
Published: April 2023

Supplementary Figure from Combined Performance of Fecal Immunochemical Tests and a Genetic Risk Score for Advanced Neoplasia Detection
Supplementary Table S1 from Effects of Black Raspberry on Dibenzo[a,l]Pyrene Diol Epoxide Induced DNA Adducts, Mutagenesis, and Tumorigenesis in the Mouse Oral Cavity
Authors: Chen Kun-Ming , Guttenplan Joseph B. , Sun Yuan-Wan , Cooper Timothy , Shalaby Nora A.E. , Kosinska Wieslawa , Benitez Gabrielle , Aliaga Cesar , Zhu Junjia , Liao Jason , Gowda Krishne , Amin Shantu , Stoner Gary , El-Bayoumy Karam
Published: April 2023

Body weight of mice treated with DB[a,l]PDE in the absence and presence of BRB.
BowelScreen leaflet from A National Bowel Cancer Screening Programme using FIT: Achievements and Challenges
Authors: O'Donoghue Diarmuid , Sheahan Kieran , MacMathuna Padraic , Stephens Richard B. , Fenlon Helen , Morrin Martina , Mooney Jenny , Fahy Lorraine E. , Mooney Therese , Smith Alan
Published: April 2023

Explanatory leaflet to participants explaining sharing of data with family doctors and colonoscopy units where relevant
Supplementary Figure 2 from Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study
Authors: Belfiore Antonino , Ciniselli Chiara Maura , Signoroni Stefano , Gariboldi Manuela , Mancini Andrea , Rivoltini Licia , Morelli Daniele , Masci Enzo , Bruno Eleonora , Macciotta Alessandra , Ricci Maria Teresa , Daveri Elena , Cattaneo Laura , Gargano Giuliana , Apolone Giovanni , Milione Massimo , Verderio Paolo , Pasanisi Patrizia , Vitellaro Marco
Published: April 2023

Boxplot reflecting the distribution of 15-PGDH expression at baseline (T0) and at six months (T2) according to the Aperio ScanScope Cytoplasm Algorithm V2. Each box indicates the 25th and 75th percentiles of the distribution. The horizontal line inside the box indicates the median and the whiskers indicate the extreme measured values; the mean value is represented by a black diamond.
Supplementary Table S2 from The Relationship Between Breast Density Change During Menopause and the Risk of Breast Cancer in Korean Women
Authors: Kang Danbee , Kim Ji-Yeon , Kim Ji-Young , Mun Han Song , Yoon Sook Ja , Lee Jieun , Han Gayeon , Im Young-Hyuck , Shin Soo-Young , Lee Se Kyung , Yu Jong-Han , Lee Kyung-Hyun , Kim Mincheol , Park Dohyun , Choi Yoon-Ho , Jeong Ok Soon , Lee Jean Hyoung , Jekal Se Yong , Choi Jong Soo , Guallar Eliseo , Chang Yoosoo , Ryu Seungho , Cho Juhee , Kang Mira
Published: April 2023

Hazard ratios (95% CI) for the incidence of breast cancer by change in breast density among participants who had scattered fibroglandular or heterogeneously dense breasts premenopause
Supplementary Figure Legend from Association of IgG Glycosylation and Esophageal Precancerosis Beyond Inflammation
Authors: Wu Zhiyuan , Pan Huiying , Liu Di , Zhou Di , Tao Lixin , Zhang Jie , Wang Xiaonan , Wang Youxin , Wang Wei , Guo Xiuhua
Published: April 2023

Supplementary Figure Legend
Supplementary Tables from IKZF1 Gene in Childhood B-cell Precursor Acute Lymphoblastic Leukemia: Interplay between Genetic Susceptibility and Somatic Abnormalities
Authors: Lopes Bruno A. , Barbosa Thayana C. , Souza Bruna K.S. , Poubel Caroline P. , Pombo-de-Oliveira Maria S. , Emerenciano Mariana
Published: April 2023

Supplementary Tables
Figure S1 from Association of IgG Glycosylation and Esophageal Precancerosis Beyond Inflammation
Authors: Wu Zhiyuan , Pan Huiying , Liu Di , Zhou Di , Tao Lixin , Zhang Jie , Wang Xiaonan , Wang Youxin , Wang Wei , Guo Xiuhua
Published: April 2023

UPLC analysis and the structures of the detected IgG glycans.
Supplementary Tables from DNA Methylation in Peripheral Blood and Risk of Gastric Cancer: A Prospective Nested Case–control Study
Authors: Chamberlain James A , Dugué Pierre-Antoine , Bassett Julie K. , Milne Roger L. , Joo Jihoon E. , Wong Ee Ming , Brinkman Maree T. , Stuart Geoffrey W. , Boussioutas Alex , Southey Melissa C. , Giles Graham G. , Mitchell Hazel , English Dallas R. , Hodge Allison M.
Published: April 2023

Table S1, Table S2
Table S4 from A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies
Authors: Sroczynski Gaby , Gogollari Artemisa , Kuehne Felicitas , Hallsson Lára R. , Widschwendter Martin , Pashayan Nora , Siebert Uwe
Published: April 2023

Results of cost-effectiveness studies evaluating ovarian cancer screening strategies: discounted cost, life years (LY), quality-adjusted life years (QALY), incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR).
Supplementary Figure S3 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma
Authors: Chung Andrew S. , Mettlen Marcel , Ganguly Debolina , Lu Tianshi , Wang Tao , Brekken Rolf A. , Hsiehchen David , Zhu Hao
Published: April 2023

Comparative whole liver section images from untreated and IgG control animals stained for CD3, CD4, and CD8.
Supplementary Figure S3 from Effects of Walnut Consumption on Colon Carcinogenesis and Microbial Community Structure
Authors: Nakanishi Masako , Chen Yanfei , Qendro Veneta , Miyamoto Shingo , Weinstock Erica , Weinstock George M. , Rosenberg Daniel W.
Published: April 2023

Immunohistochemical analyses of colon tumors in Study 2.
Supplementary Figure 8 from Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrow–Derived Cells
Authors: Kuznetsov Hanna S. , Marsh Timothy , Markens Beth A. , Castaño Zafira , Greene-Colozzi April , Hay Samantha A. , Brown Victoria E. , Richardson Andrea L. , Signoretti Sabina , Battinelli Elisabeth M. , McAllister Sandra S.
Published: April 2023

PDF file - 89K, Aspirin treatment does not affect growth kinetics of the LBC instigator or circulating platelet counts
Supplementary Figure 7 from Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrow–Derived Cells
Authors: Kuznetsov Hanna S. , Marsh Timothy , Markens Beth A. , Castaño Zafira , Greene-Colozzi April , Hay Samantha A. , Brown Victoria E. , Richardson Andrea L. , Signoretti Sabina , Battinelli Elisabeth M. , McAllister Sandra S.
Published: April 2023

PDF file - 117K, Tumor specimen from a patient with with clear cell renal cell carcinoma responders to the LBC environment in the systemic instigation xenograft model
Supplementary Figure 5 from Gene Signatures Associated with Mouse Postnatal Hindbrain Neural Stem Cells and Medulloblastoma Cancer Stem Cells Identify Novel Molecular Mediators and Predict Human Medulloblastoma Molecular Classification
Authors: Corno Daniela , Pala Mauro , Cominelli Manuela , Cipelletti Barbara , Leto Ketty , Croci Laura , Barili Valeria , Brandalise Federico , Melzi Raffaella , Di Gregorio Alessandra , Sergi Lucia Sergi , Politi Letterio Salvatore , Piemonti Lorenzo , Bulfone Alessandro , Rossi Paola , Rossi Ferdinando , Consalez Gian Giacomo , Poliani Pietro Luigi , Galli Rossella
Published: April 2023

PDF file - 229K, WNT pathway-related molecular mediators, such as beta-catenin, Lef1, Fzd6 and Wif1, are up regulated in tumors generated by tumorigenic CSCs in vivo and in tumorigenic CSC lines in vitro
Supplementary Figure 4 from Gene Signatures Associated with Mouse Postnatal Hindbrain Neural Stem Cells and Medulloblastoma Cancer Stem Cells Identify Novel Molecular Mediators and Predict Human Medulloblastoma Molecular Classification
Authors: Corno Daniela , Pala Mauro , Cominelli Manuela , Cipelletti Barbara , Leto Ketty , Croci Laura , Barili Valeria , Brandalise Federico , Melzi Raffaella , Di Gregorio Alessandra , Sergi Lucia Sergi , Politi Letterio Salvatore , Piemonti Lorenzo , Bulfone Alessandro , Rossi Paola , Rossi Ferdinando , Consalez Gian Giacomo , Poliani Pietro Luigi , Galli Rossella
Published: April 2023

PDF file - 213K, Gene signatures distinguishing the different MB CSC populations segregate distinct human MB molecular subgroups, with MB1_EXCLUSIVE gene signature distinguishing the WNT molecular subgroup
Supplementary Figure 3 from Gene Signatures Associated with Mouse Postnatal Hindbrain Neural Stem Cells and Medulloblastoma Cancer Stem Cells Identify Novel Molecular Mediators and Predict Human Medulloblastoma Molecular Classification
Authors: Corno Daniela , Pala Mauro , Cominelli Manuela , Cipelletti Barbara , Leto Ketty , Croci Laura , Barili Valeria , Brandalise Federico , Melzi Raffaella , Di Gregorio Alessandra , Sergi Lucia Sergi , Politi Letterio Salvatore , Piemonti Lorenzo , Bulfone Alessandro , Rossi Paola , Rossi Ferdinando , Consalez Gian Giacomo , Poliani Pietro Luigi , Galli Rossella
Published: April 2023

PDF file - 157K, MB CSC lines are Sonic Hedgehog (Shh) pathway-independent, as their survival/proliferation is not affected by cyclopamine treatment and Smo silencing
Supplementary Methods from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1
Authors: Laine Anni , Sihto Harri , Come Christophe , Rosenfeldt Mathias T. , Zwolinska Aleksandra , Niemelä Minna , Khanna Anchit , Chan Edward K. , Kähäri Veli-Matti , Kellokumpu-Lehtinen Pirkko-Liisa , Sansom Owen J. , Evan Gerard I. , Junttila Melissa R. , Ryan Kevin M. , Marine Jean-Christophe , Joensuu Heikki , Westermarck Jukka
Published: April 2023

Supplementary Methods PDF file - 98K, Supplementary materials and methods
Supplementary Figure 4 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1
Authors: Laine Anni , Sihto Harri , Come Christophe , Rosenfeldt Mathias T. , Zwolinska Aleksandra , Niemelä Minna , Khanna Anchit , Chan Edward K. , Kähäri Veli-Matti , Kellokumpu-Lehtinen Pirkko-Liisa , Sansom Owen J. , Evan Gerard I. , Junttila Melissa R. , Ryan Kevin M. , Marine Jean-Christophe , Joensuu Heikki , Westermarck Jukka
Published: April 2023

Supplementary Figure 4 PDF file - 269K, Characterization of hypomorphic CIP2A HOZ mice
Supplementary Tables 1, 3, 5, 8-9, 11-12, 14, Figures 1-14, Methods from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Authors: Geng Huimin , Brennan Sarah , Milne Thomas A. , Chen Wei-Yi , Li Yushan , Hurtz Christian , Kweon Soo-Mi , Zickl Lynette , Shojaee Seyedmehdi , Neuberg Donna , Huang Chuanxin , Biswas Debabrata , Xin Yuan , Racevskis Janis , Ketterling Rhett P. , Luger Selina M. , Lazarus Hillard , Tallman Martin S. , Rowe Jacob M. , Litzow Mark R. , Guzman Monica L. , Allis C. David , Roeder Robert G. , Müschen Markus , Paietta Elisabeth , Elemento Olivier , Melnick Ari M.
Published: April 2023

PDF file - 839K
Supplementary Table 7 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Authors: Geng Huimin , Brennan Sarah , Milne Thomas A. , Chen Wei-Yi , Li Yushan , Hurtz Christian , Kweon Soo-Mi , Zickl Lynette , Shojaee Seyedmehdi , Neuberg Donna , Huang Chuanxin , Biswas Debabrata , Xin Yuan , Racevskis Janis , Ketterling Rhett P. , Luger Selina M. , Lazarus Hillard , Tallman Martin S. , Rowe Jacob M. , Litzow Mark R. , Guzman Monica L. , Allis C. David , Roeder Robert G. , Müschen Markus , Paietta Elisabeth , Elemento Olivier , Melnick Ari M.
Published: April 2023

XLS file - 74K, DNA methylation and gene expression signature of BCR-ABL1-positive B-ALL
Supplementary Figure 6 from Hypoxia-Dependent Modification of Collagen Networks Promotes Sarcoma Metastasis
Authors: Eisinger-Mathason T.S. Karin , Zhang Minsi , Qiu Qiong , Skuli Nicolas , Nakazawa Michael S. , Karakasheva Tatiana , Mucaj Vera , Shay Jessica E.S. , Stangenberg Lars , Sadri Navid , Puré Ellen , Yoon Sam S. , Kirsch David G. , Simon M. Celeste
Published: April 2023

Supplementary Figure 6 - PDF file 110K, Expression of WT and mutant PLOD2 in sarcoma cells
Supplementary Figure 5 from Hypoxia-Dependent Modification of Collagen Networks Promotes Sarcoma Metastasis
Authors: Eisinger-Mathason T.S. Karin , Zhang Minsi , Qiu Qiong , Skuli Nicolas , Nakazawa Michael S. , Karakasheva Tatiana , Mucaj Vera , Shay Jessica E.S. , Stangenberg Lars , Sadri Navid , Puré Ellen , Yoon Sam S. , Kirsch David G. , Simon M. Celeste
Published: April 2023

Supplementary Figure 5 - PDF file 173K, HIF1{alpha} and PLOD2 mediate migration via a cell extrinsic mechanism in HT-1080 cells
Supplementary Figure 7 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Authors: Aarts Marieke , Sharpe Rachel , Garcia-Murillas Isaac , Gevensleben Heidrun , Hurd Melissa S. , Shumway Stuart D. , Toniatti Carlo , Ashworth Alan , Turner Nicholas C.
Published: April 2023

PDF file - 101K, CDK1 and cyclin B1 expression levels in breast cancer cell lines
Supplementary Figure 6 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Authors: Aarts Marieke , Sharpe Rachel , Garcia-Murillas Isaac , Gevensleben Heidrun , Hurd Melissa S. , Shumway Stuart D. , Toniatti Carlo , Ashworth Alan , Turner Nicholas C.
Published: April 2023

PDF file - 108K, Premature mitosis is prevented by p53, p21 and CDK1 activity
Supplementary Figure 4 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Authors: Aarts Marieke , Sharpe Rachel , Garcia-Murillas Isaac , Gevensleben Heidrun , Hurd Melissa S. , Shumway Stuart D. , Toniatti Carlo , Ashworth Alan , Turner Nicholas C.
Published: April 2023

PDF file - 135K, HU and MK-1775 combination treatment induces apoptosis
Supplementary Figure 3 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Authors: Aarts Marieke , Sharpe Rachel , Garcia-Murillas Isaac , Gevensleben Heidrun , Hurd Melissa S. , Shumway Stuart D. , Toniatti Carlo , Ashworth Alan , Turner Nicholas C.
Published: April 2023

PDF file - 193K, Time course and dose analysis of gemcitabine and MK-1775
Supplementary Figure 2 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Authors: Aarts Marieke , Sharpe Rachel , Garcia-Murillas Isaac , Gevensleben Heidrun , Hurd Melissa S. , Shumway Stuart D. , Toniatti Carlo , Ashworth Alan , Turner Nicholas C.
Published: April 2023

PDF file - 306K, Gemcitabine and MK-1775 combination in various breast cancer cell lines
Supplementary Table S1 from Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
Authors: Polkinghorn William R. , Parker Joel S. , Lee Man X. , Kass Elizabeth M. , Spratt Daniel E. , Iaquinta Phillip J. , Arora Vivek K. , Yen Wei-Feng , Cai Ling , Zheng Deyou , Carver Brett S. , Chen Yu , Watson Philip A. , Shah Neel P. , Fujisawa Sho , Goglia Alexander G. , Gopalan Anuradha , Hieronymus Haley , Wongvipat John , Scardino Peter T. , Zelefsky Michael J. , Jasin Maria , Chaudhuri Jayanta , Powell Simon N. , Sawyers Charles L.
Published: April 2023

Supplementary Table S1 - PDF file 170K, Gene set enrichment analysis of ARN-509-treated LNCaP-AR xenografts